首页> 外文期刊>European Journal of Pharmacology: An International Journal >Distinct modulation of telomere length in two T-lymphoblastic leukemia cell lines by cytotoxic nucleoside phosphonates PMEG and PMEDAP.
【24h】

Distinct modulation of telomere length in two T-lymphoblastic leukemia cell lines by cytotoxic nucleoside phosphonates PMEG and PMEDAP.

机译:细胞毒性核苷膦酸酯PMEG和PMEDAP对两种T淋巴细胞白血病细胞系中端粒长度的不同调节。

获取原文
获取原文并翻译 | 示例
           

摘要

We have previously shown that PMEG diphosphate (PMEGpp) and PMEDAP diphosphate (PMEDAPpp) inhibit the enzymatic activity of human telomerase in a cell-free assay. Here, we investigated the ability of PMEG and PMEDAP to induce telomere shortening and telomerase inhibition at both transcriptional and activity level in T-lymphoblastic leukemia cells CCRF-CEM and MOLT-4. At defined time points (3days and 9weeks), the telomerase activity and relative levels of hTERT and c-myc mRNA were determined using real-time RT-PCR. Telomere length was measured by the flow-FISH method. Both PMEDAP and PMEG induced telomere shortening in CCRF-CEM cells after 9weeks of exposure by 50% and 20%, respectively, without major impairment of telomerase activity. The effect of the tested compounds on telomere length in MOLT-4 cells was the opposite, with telomere elongation by 50% and 40% after 9-week treatment with PMEDAP and PMEG, respectively. At this time point, telomerase activity in MOLT-4 cells appeared to be slightly higher than that of CCRF-CEM cells, nevertheless no correlation between telomerase activity and telomere length was found. Both compounds down-regulated the expression of hTERT and c-myc mRNA in CCRF-CEM and MOLT-4 cells at 72h in a concentration-dependent manner while prolonged exposure to PMEG or PMEDAP for 9weeks had weaker effects. In conclusion, PMEDAP and PMEG are able to modulate telomere length in leukemic cells and this effect is cell-type specific. It is neither due to direct telomerase inhibition nor impairment of hTERT expression and it is likely to be telomerase-independent.
机译:我们以前已经证明,无细胞测定中PMEG二磷酸(PMEGpp)和PMEDAP二磷酸(PMEDAPpp)抑制人端粒酶的酶活性。在这里,我们研究了PMEG和PMEDAP在T淋巴细胞白血病细胞CCRF-CEM和MOLT-4的转录和活性水平上诱导端粒缩短和端粒酶抑制的能力。在确定的时间点(3天和9周),使用实时RT-PCR测定端粒酶活性以及hTERT和c-myc mRNA的相对水平。端粒长度通过flow-FISH方法测量。暴露9周后,PMEDAP和PMEG均可分别在CCRF-CEM细胞中诱导端粒缩短50%和20%,而端粒酶活性没有明显降低。被测化合物对MOLT-4细胞端粒长度的影响是相反的,在分别用PMEDAP和PMEG处理9周后,端粒伸长分别为50%和40%。此时,MOLT-4细胞中的端粒酶活性似乎略高于CCRF-CEM细胞,但是端粒酶活性与端粒长度之间没有相关性。两种化合物在72h均以浓度依赖性方式下调CCRF-CEM和MOLT-4细胞中hTERT和c-myc mRNA的表达,而长时间暴露于PMEG或PMEDAP 9周则作用较弱。总之,PMEDAP和PMEG能够调节白血病细胞中的端粒长度,这种作用是细胞类型特异性的。它既不是由于端粒酶的直接抑制也不是hTERT表达的损伤,并且可能与端粒酶无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号